Abstract

The specific objective of this contract will be to provide the Investigational Drug Branch (IDB), CTEP, DCT, NCI, with Phase I clinical evaluations of investigational new drugs which are developed through the DCT Linear Array and are sponsored to the Food and Drug Administration (FDA) under an IND held by DCT. The objective of Phase I studies is to provide the parameters and characteristics of drug toxicity, the maximally tolerated dose, and a recommended Phase II dose.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM027546-005
Application #
3610124
Study Section
Project Start
1982-04-01
Project End
1985-07-01
Budget Start
1985-04-01
Budget End
1985-07-01
Support Year
Fiscal Year
1985
Total Cost
Indirect Cost

  Institution

Name
Memorial Hospital for Cancer & Allied Di
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10021

  Publications

Bajorin, D F; Bosl, G J; Alcock, N W et al. (1986) Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res 46:5969-72
Warrell Jr, R P; Coonley, C J; Gee, T S (1985) Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol 3:617-21
Casper, E S; Mittelman, A; Kelson, D et al. (1985) Phase I clinical trial of fludarabine phosphate (F-ara-AMP). Cancer Chemother Pharmacol 15:233-5